The MTB was established to review challenging cancer cases with molecular genetic testing results that require additional input from colleagues with varying expertise. Somatic or germline alterations are evaluated on their anticipated effects on tumor pathophysiology, and members of the molecular tumor board assess treatment options and clinical trial participation opportunities, as well as implications for risk assessment and interventions for germline variants.
